BNET Industries
Market Cap:$101.5B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Sanofi-Aventis Recalls 800 Thousand Doses Of Swine Flu Vaccine - Quick Facts
-
Warner Chilcott Affirms Global Marketing and Collaboration Agreement With Sanofi-Aventis
-
Common heart rhythm problem on the rise in the U.S.
-
Sanofi-Aventis and Alopexx sign collaboration agreement
-
Sanofi-Aventis in research pact with CalTech
-
Generex enters insulin supply deal for Oral-lyn
-
86. Sanofi
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
Early and Often: A Drug Investor's Dream
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
News & Analysis
Filter by
fda and sanofi-aventis - All News and Analysis
14 Drug Companies Cited for Misleading Google Ads
BNET
- 2009-04-07
The FDA cited 14 drug companies for misleading advertising in sponsored ads among Google search results. Those cited: Biogen Idec, Sanofi Aventis, GlaxoSmithKline, Forest Laboratories, Cephalon, Bayer, Johnson & Johnson, Pfizer, Novartis , Genentech, Boehringer Ingelheim, Merck, Hoffman-LaRoche, and Eli Lilly. The citations, sent...
Key US drug panel rejects Sanofi's obesity pill
- 2007-06-13
WASHINGTON AFP — A US Food and Drug Administration panel of experts concluded Wednesday that pharmaceutical giant Sanofi-Aventis's obesity treatment Acomplia was unsafe and should not be sold in the United States. The 14 doctors on the advisory committee voted unanimously against allowing the French company's diet drug to...
Shares in Sanofi fall after anti-obesity drug setback
- 2006-02-20
PARIS AFP — The price of shares in French pharmaceutical group Sanofi-Aventis fell sharply after the company suffered a setback from regulatory authorities in the United States over its hotly awaited anti-obesity drug. In early afternoon trading, the price of shares in the group was showing a fall of...
Novo Nordisk's new diabetes drug approved in US
- 2005-06-17
COPENHAGEN AFP — The US Food and Drug Administration FDA has given the green light for the sale of Levemir, a long-acting insulin analogue drug for the treatment of diabetes, Danish pharmaceutical maker Novo Nordisk revealed. The drug has already been approved in 37 countries, including the European Union...
US FDA accepts diabetes drug application by Sanofi-Aventis, Pfizer
- 2005-03-02
PARIS AFP — The US Food and Drug Administration has accepted a new drug application by French pharmaceutical group Sanofi-Aventis and Pfizer of the United States for Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, the companies said. The companies want...
- 1
| Volume | 1,027,420 |
| Shares Outstanding | 2.6B |
| Market Cap | 101.5B |
| Year High | 40.28 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.4525 |
| Dividend | 1.0639 |
| Yield | 2.7584 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
Presented by American Express